journal article
Open Access
Sep 01, 2024
Fatigue in Parkinson’s disease—A narrative review
Abstract
Abstract
Although fatigue is a common non-motor symptom of Parkinson’s disease (PD), it is often overlooked during routine assessments of individuals with PD. This can be attributed partly to the lack of recognition of this symptom and the coexistence of other confounding symptoms, such as apathy, somnolence, and depression. However, considering the effects of fatigue on the quality of life (QoL) of individuals with PD, it is crucial to review its causes and management strategies. According to the diagnostic criteria for PD-related fatigue, patients must report significantly reduced energy levels or an increased perception of effort disproportionate to their attempted activities. PD-related fatigue can be divided into central and peripheral types. Peripheral fatigue involves muscle weakness and impaired voluntary movements, influenced by tremors and bradykinesia. Central fatigue, which can be divided into mental and physical subtypes, manifests as persistent exhaustion without peripheral motor deficits. The pathophysiology of central fatigue in PD is complex. It involves dysfunction in the striato–limbic–serotonergic system, imbalance of neurotransmitters (dopamine and serotonin), as well as hypoconnectivity in the supplementary motor area and hyperconnectivity in the default mode network. Emerging evidence suggests that neuroinflammation and autonomic dysfunction may contribute to fatigue. Fatigue in PD is treated using pharmacological therapies (such as dopaminergic agents, antidepressants, methylphenidate, and modafinil) and non-pharmacological interventions (such as exercise). There is a gap in the current understanding, measurement, and treatment of fatigue in PD. A deeper understanding of the patho-mechanisms of fatigue in PD is needed to establish evidence-based treatment guidelines. The QoL of individuals with PD can be improved by focusing on person-centered interventions targeting fatigue.
Although fatigue is a common non-motor symptom of Parkinson’s disease (PD), it is often overlooked during routine assessments of individuals with PD. This can be attributed partly to the lack of recognition of this symptom and the coexistence of other confounding symptoms, such as apathy, somnolence, and depression. However, considering the effects of fatigue on the quality of life (QoL) of individuals with PD, it is crucial to review its causes and management strategies. According to the diagnostic criteria for PD-related fatigue, patients must report significantly reduced energy levels or an increased perception of effort disproportionate to their attempted activities. PD-related fatigue can be divided into central and peripheral types. Peripheral fatigue involves muscle weakness and impaired voluntary movements, influenced by tremors and bradykinesia. Central fatigue, which can be divided into mental and physical subtypes, manifests as persistent exhaustion without peripheral motor deficits. The pathophysiology of central fatigue in PD is complex. It involves dysfunction in the striato–limbic–serotonergic system, imbalance of neurotransmitters (dopamine and serotonin), as well as hypoconnectivity in the supplementary motor area and hyperconnectivity in the default mode network. Emerging evidence suggests that neuroinflammation and autonomic dysfunction may contribute to fatigue. Fatigue in PD is treated using pharmacological therapies (such as dopaminergic agents, antidepressants, methylphenidate, and modafinil) and non-pharmacological interventions (such as exercise). There is a gap in the current understanding, measurement, and treatment of fatigue in PD. A deeper understanding of the patho-mechanisms of fatigue in PD is needed to establish evidence-based treatment guidelines. The QoL of individuals with PD can be improved by focusing on person-centered interventions targeting fatigue.
Topics
No keywords indexed for this article. Browse by subject →
References
103
[1]
Kluger "Parkinson’s disease‐related fatigue: A case definition and recommendations for clinical research" Mov Disord (2016) 10.1002/mds.26511
[2]
Katunina "The epidemiology of nonmotor symptoms in Parkinson’s disease (Cohort and Other Studies)" International Review of Neurobiology (2017) 10.1016/bs.irn.2017.05.012
[3]
The Onset of Nonmotor Symptoms in Parkinson's disease (The ONSET PDStudy)
Claustre Pont‐Sunyer, Anna Hotter, Carles Gaig et al.
Movement Disorders
2015
10.1002/mds.26077
[4]
Friedman "Fatigue in Parkinson’s disease: A review" Mov Disord (2007) 10.1002/mds.21240
[5]
Lou "Levodopa improves physical fatigue in Parkinson’s disease: A double‐blind, placebo‐controlled, crossover study" Mov Disord (2003) 10.1002/mds.10505
[6]
Ongre "Fatigue in early Parkinson’s disease: The Norwegian ParkWest study" Eur J Neurol (2017) 10.1111/ene.13161
[7]
Ou "Progression of fatigue in early Parkinson’s disease: A 3-Year prospective cohort study" Front Aging Neurosci (2021) 10.3389/fnagi.2021.701906
[8]
Zhou "Characteristics of fatigue in Parkinson’s disease: A longitudinal cohort study" Front Aging Neurosci (2023) 10.3389/fnagi.2023.1133705
[9]
Sanchez-Luengos "Predictors of health-related quality of life in Parkinson’s disease: The impact of overlap between health-related quality of life and clinical measures" Qual Life Res (2022) 10.1007/s11136-022-03187-y
[10]
Havlikova "Impact of fatigue on quality of life in patients with Parkinson’s disease" Eur J Neurol (2008) 10.1111/j.1468-1331.2008.02103.x
[11]
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results
Christopher G. Goetz, Barbara C. Tilley, Stephanie R. Shaftman et al.
Movement Disorders
2008
10.1002/mds.22340
[12]
Brown "The Parkinson fatigue scale" Parkinsonism Relat Disord (2005) 10.1016/j.parkreldis.2004.07.007
[13]
Friedman "Fatigue in Parkinson’s disease: Report from a multidisciplinary symposium" NPJ Parkinsons Dis (2016) 10.1038/npjparkd.2015.25
[14]
Siciliano "Validation of new diagnostic criteria for fatigue in patients with Parkinson disease" Eur J Neurol (2022) 10.1111/ene.15411
[15]
Siciliano "Fatigue in Parkinson’s disease: A systematic review and meta‐analysis" Mov Disord (2018) 10.1002/mds.27461
[16]
Lin "Triggers and alleviating factors for fatigue in Parkinson’s disease" PLoS One (2021) 10.1371/journal.pone.0245285
[17]
Chou "Association between autonomic dysfunction and fatigue in Parkinson disease" J Neurol Sci (2017) 10.1016/j.jns.2017.04.023
[18]
Jason "What is fatigue? Pathological and nonpathological fatigue" PM R (2010) 10.1016/j.pmrj.2010.03.028
[19]
Kluger "Fatigue and fatigability in neurologic illnesses: Proposal for a unified taxonomy" Neurology (2013) 10.1212/wnl.0b013e31827f07be
[20]
Chaudhuri "Fatigue in neurological disorders" Lancet (2004) 10.1016/s0140-6736(04)15794-2
[21]
Finsterer "Fatigue in healthy and diseased individuals" Am J Hosp Palliat Med (2014) 10.1177/1049909113494748
[22]
Friedman "Fatigue in Parkinson’s disease" Expert Opin Pharmacother (2011) 10.1517/14656566.2011.587120
[23]
Friedman "Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson’s disease" Mov Disord (2010) 10.1002/mds.22989
[24]
Schifitto "Fatigue in levodopa-naïve subjects with Parkinson disease" Neurology (2008) 10.1212/01.wnl.0000324862.29733.69
[25]
Sauerbier "Non motor subtypes and Parkinson’s disease" Parkinsonism Relat Disord (2016) 10.1016/j.parkreldis.2015.09.027
[26]
Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction
N. Pavese, V. Metta, S. K. Bose et al.
Brain
2010
10.1093/brain/awq268
[27]
Kostić "The pathophysiology of fatigue in Parkinson’s disease and its pragmatic management" Mov Disord Clin Pract (2016) 10.1002/mdc3.12343
[28]
Bolam "Synaptic organisation of the basal ganglia" J Anat (2000) 10.1046/j.1469-7580.2000.19640527.x
[29]
Chaudhuri "Fatigue and basal ganglia" J Neurol Sci (2000) 10.1016/s0022-510x(00)00411-1
[30]
Tessitore "Functional connectivity underpinnings of fatigue in "Drug-Naïve" patients with Parkinson’s disease" Mov Disord (2016) 10.1002/mds.26650
[31]
Andrews‐Hanna "The default network and self‐generated thought: Component processes, dynamic control, and clinical relevance" Ann N Y Acad Sci (2014) 10.1111/nyas.12360
[32]
Kenangil "The relation of testosterone levels with fatigue and apathy in Parkinson’s disease" Clin Neurol Neurosurg (2009) 10.1016/j.clineuro.2008.11.019
[33]
Nakamura "Does cardiovascular autonomic dysfunction contribute to fatigue in Parkinson’s disease?" Mov Disord (2011) 10.1002/mds.23744
[34]
Bower "Cancer-related fatigue: Links with inflammation in cancer patients and survivors" Brain Behav Immun (2007) 10.1016/j.bbi.2007.03.013
[35]
Wang "Plasma TNF-α and phosphorylated α-syn are associated with fatigue in patients with Parkinson’s disease" J Neuroimmunol (2023) 10.1016/j.jneuroim.2023.578222
[36]
Herlofson "Inflammation and fatigue in early, untreated Parkinson’s Disease" Acta Neurol Scand (2018) 10.1111/ane.12977
[37]
Pereira "IL-6 serum levels are elevated in Parkinson’s disease patients with fatigue compared to patients without fatigue" J Neurol Sci (2016) 10.1016/j.jns.2016.09.030
[38]
Lindqvist "Cerebrospinal fluid inflammatory markers in Parkinson’s disease – Associations with depression, fatigue, and cognitive impairment" Brain Behav Immun (2013) 10.1016/j.bbi.2013.07.007
[39]
Eyre "Neuroplastic changes in depression: A role for the immune system" Psychoneuroendocrinology (2012) 10.1016/j.psyneuen.2012.03.019
[40]
Miller "Cytokine targets in the brain: Impact on neurotransmitters and neurocircuits: Review: Cytokine Targets in the Brain" Depress Anxiety (2013) 10.1002/da.22084
[41]
Prell "Biomarkers for dementia, fatigue, and depression in Parkinson’s Disease" Front Neurol (2019) 10.3389/fneur.2019.00195
[42]
Zhang "Abnormal resting‐state neural activity and connectivity of fatigue in Parkinson’s Disease" CNS Neurosci Ther (2017) 10.1111/cns.12666
[43]
Li "Alterations in regional homogeneity of resting-state brain activity in fatigue of Parkinson’s disease" J Neural Transm (2017) 10.1007/s00702-017-1748-1
[44]
Cho "Fatigue in Parkinson’s disease: The contribution of cerebral metabolic changes" Hum Brain Mapp (2017) 10.1002/hbm.23360
[45]
Abe "Fatigue in patients with Parkinson’s Disease" Behav Neurol (2000) 10.1155/2000/580683
[46]
Chou "Neuroimaging and clinical predictors of fatigue in Parkinson disease" Parkinsonism Relat Disord (2016) 10.1016/j.parkreldis.2015.11.029
[47]
Janssen Daalen "Digital biomarkers for non-motor symptoms in Parkinson’s disease: The state of the art" NPJ Digit Med (2024) 10.1038/s41746-024-01144-2
[48]
Huang "Detection of mental fatigue state with wearable ECG devices" Int J Med Inf (2018) 10.1016/j.ijmedinf.2018.08.010
[49]
Tseng "Digital biomarker of mental fatigue" NPJ Digit Med (2021) 10.1038/s41746-021-00415-6
[50]
Eidem "Fatigue in Parkinson’s Disease: A proteomic study of cerebrospinal fluid" Mov Disord (2024) 10.1002/mds.29715
Showing 50 of 103 references
Metrics
5
Citations
103
References
Details
- Published
- Sep 01, 2024
- Vol/Issue
- 7(3)
- Pages
- 157-170
- License
- View
Authors
Cite This Article
Baikuntha Panigrahi, Kanchana S. Pillai, Divya M. Radhakrishnan, et al. (2024). Fatigue in Parkinson’s disease—A narrative review. Annals of Movement Disorders, 7(3), 157-170. https://doi.org/10.4103/aomd.aomd_99_24